Cancer risk and genotype–phenotype correlations in PTEN hamartoma tumor syndrome
Marry H. Nieuwenhuis(Netherlands Consortium for Healthy Ageing), Hans F. A. Vasen(Leiden University Medical Center), Stefan Aretz(University of Bonn), Karl Heinimann(University Hospital of Basel), Noralane M. Lindor(Mayo Clinic in Arizona), C. Marleen Kets, Chrystelle Colas(Institut Curie), Maureen Murphy‐Ryan(Mayo Clinic in Arizona), Allan D. Spigelman(Cancer Institute of New South Wales), Susanne Timshel, Helger G. Yntema(Radboud University Nijmegen), D. Gareth Evans(Manchester Academic Health Science Centre), Pål Møller(Unknown), Fiona Douglas(University of Southern California), Shirley V. Hodgson(St George's, University of London), E. Gómez(Maastricht University Medical Centre), Maran J.W. Olderode-Berends(University Medical Center Groningen), Frederik J. Hes(Leiden University Medical Center)
Cited by 163
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma
|The American Journal of Human Genetics|2001|1.1k
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
|JNCI Journal of the National Cancer Institute|2013|946
Germline <i>BRCA</i> Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
|Journal of Clinical Oncology|2013|833